AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-30
$294.89+1.41%
Close 2026-10-30 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-30
Research Workspace
Put ABBV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Increase adjusted diluted EPS to at least $14.28 in 2026: Comparison needs review.
View ThesisRevenue growth is accelerating — up about 10% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 12%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationRelatively steady — typically moves about 1% a day.
View RiskABBV’s immunology portfolio growth and pipeline expansion are the central case, supported by robust cash-backed profits. The available earnings history does not establish a current revenue-growth trend or latest result. ABBV trades at 23× P/E versus a 22× peer median. The price reflects less growth than our forecast. The primary pillar is 2026 adjusted diluted EPS of at least $14.28, but its comparison needs review. Our model puts the next-quarter miss near 10%. Peer multiples imply a price about 13% below where it trades; the thesis is on watch.
Trailing returns as of 2026-10-30. ABBV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 30 analysts currently covering ABBV (as of Oct 2026).
Based on 14 Wall Street analysts offering 12-month price targets for ABBV in the last 4 months.
Continue this research
Compare ABBV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ABBV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ABBV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase adjusted diluted EPS guidance
Higher revenue outlook and specified adjusted EPS guidance support the objective of growing adjusted EPS.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $294.89
The last 12 months of price, then the range of analyst 12-month targets from today’s $294.89.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance immunology portfolio growth and pipeline expansion
Revenue growth in immunology and neuroscience supports portfolio growth, though the headline lacks magnitude.
Advances: Advance immunology portfolio growth and pipeline expansion
BLA submission advances pipeline expansion, though approval and commercial impact remain uncertain.
Advances: Advance immunology portfolio growth and pipeline expansion
Positive Phase 3 results support immunology pipeline expansion and potential future growth.
Advances: Advance immunology portfolio growth and pipeline expansion
Breakthrough designations enhance pipeline growth potential.
Threatens: Maintain and grow dividend payouts
Dividend sustainability questioned due to payout exceeding earnings.
Advances: Advance immunology portfolio growth and pipeline expansion
Positive results enhance AbbVie's immunology portfolio growth.
Threatens: Increase adjusted diluted EPS guidance
Lower EPS guidance may hinder growth expectations.
